UnitedHealth Group (UNH) Price Target Raised to $270.00

UnitedHealth Group (NYSE:UNH) had its price target upped by stock analysts at Argus to $270.00 in a research report issued to clients and investors on Thursday. The firm presently has a “buy” rating on the healthcare conglomerate’s stock. Argus’ target price suggests a potential upside of 10.95% from the company’s previous close.

Several other equities analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $219.00 price target on the stock in a report on Thursday, September 21st. Citigroup increased their price target on shares of UnitedHealth Group from $213.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. Leerink Swann reiterated a “buy” rating and issued a $240.00 price target (up previously from $225.00) on shares of UnitedHealth Group in a report on Wednesday, October 18th. Cantor Fitzgerald reiterated a “buy” rating and issued a $208.00 price target on shares of UnitedHealth Group in a report on Tuesday, October 17th. Finally, Jefferies Group increased their price target on shares of UnitedHealth Group from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, October 13th. Two analysts have rated the stock with a hold rating and twenty-six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $243.22.

UnitedHealth Group (UNH) traded up $0.19 on Thursday, hitting $243.35. 4,289,381 shares of the stock traded hands, compared to its average volume of 3,050,000. UnitedHealth Group has a 12-month low of $156.49 and a 12-month high of $244.35. The company has a current ratio of 0.73, a quick ratio of 0.70 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $235,290.00, a P/E ratio of 22.72, a P/E/G ratio of 1.42 and a beta of 0.66.

UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings data on Tuesday, January 16th. The healthcare conglomerate reported $2.59 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.09. UnitedHealth Group had a net margin of 5.25% and a return on equity of 21.29%. The firm had revenue of $52.06 billion for the quarter, compared to the consensus estimate of $51.57 billion. During the same quarter in the prior year, the company posted $2.11 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. research analysts expect that UnitedHealth Group will post 12.52 EPS for the current fiscal year.

In other UnitedHealth Group news, CEO Larry C. Renfro sold 22,598 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $221.75, for a total value of $5,011,106.50. Following the sale, the chief executive officer now owns 195,314 shares in the company, valued at approximately $43,310,879.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Kenneth Irwin Shine sold 457 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $211.03, for a total value of $96,440.71. The disclosure for this sale can be found here. In the last 90 days, insiders sold 33,655 shares of company stock worth $7,469,083. Insiders own 0.89% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in UNH. Marshall Wace LLP lifted its position in shares of UnitedHealth Group by 441.4% during the 2nd quarter. Marshall Wace LLP now owns 13,935 shares of the healthcare conglomerate’s stock valued at $2,578,000 after buying an additional 11,361 shares in the last quarter. American Century Companies Inc. lifted its position in shares of UnitedHealth Group by 16.9% during the 2nd quarter. American Century Companies Inc. now owns 4,703,113 shares of the healthcare conglomerate’s stock valued at $872,051,000 after buying an additional 681,111 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of UnitedHealth Group by 5.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 3,656,975 shares of the healthcare conglomerate’s stock valued at $678,077,000 after buying an additional 183,401 shares in the last quarter. Essex Financial Services Inc. lifted its position in shares of UnitedHealth Group by 12.3% during the 2nd quarter. Essex Financial Services Inc. now owns 8,846 shares of the healthcare conglomerate’s stock valued at $1,640,000 after buying an additional 967 shares in the last quarter. Finally, Bainco International Investors lifted its position in shares of UnitedHealth Group by 5.4% during the 3rd quarter. Bainco International Investors now owns 82,676 shares of the healthcare conglomerate’s stock valued at $16,192,000 after buying an additional 4,202 shares in the last quarter. Institutional investors and hedge funds own 86.09% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/21/unitedhealth-group-unh-price-target-raised-to-270-00.html.

About UnitedHealth Group

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Leave a Reply